Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study

Cancer Science

Volumn 107, Issue 2, 2016, Pages 162-167

  Sueoka Aragane, Naoko ^a   Katakami, Nobuyuki ^b   Satouchi, Miyako ^c   Yokota, Soichiro ^d   Aoe, Keisuke ^e   Iwanaga, Kentaro ^f   Otsuka, Kojiro ^g   Morita, Satoshi ^h   Kimura, Shinya ^a   Negoro, Shunichi ^c  

^a SAGA UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d TONEYAMA NATIONAL HOSPITAL   (Japan)

^e NATIONAL SANYO HOSPITAL   (Japan)

^f Saga Ken Medical Centre Koseikan   (Japan)

^g KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^h KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA; ErbB 1; Lung neoplasms; Molecular targeted therapy; Mutation

Indexed keywords

BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PLASMA DNA; T790M PROTEIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; EXON; FEMALE; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; BLOOD; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 84959039844     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12847     Document Type: Article

References (26)

1. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702-11.
2. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-38.
3. Cross DA, Ashton SE, Ghiorghiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-61.
4. Walter AO, Sjin RT, Haringsma HJ et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013; 3: 1404-15.
5. Diehl F, Schmidt K, Choti MA et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-90.
6. Taniguchi K, Uchida J, Nishino K et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17: 7808-15.
7. Forshew T, Murtaza M, Parkinson C et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4: 136ra68.
8. Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-12.
9. Dawson SJ, Tsui DW, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199-209.
10. Nakamura T, Sueoka-Aragane N, Iwanaga K et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011; 6: 1639-48.
11. Goldstrow P, Crowley J, Chansky K et al. The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14.
12. Nakamura T, Sueoka-Aragane N, Iwanaga K et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012; 7: 1369-81.
13. Li W, Ren S, Li J et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 2014; 84: 295-300.
14. Godin-Heymann N, Bryant I, Rivera MN et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007; 67: 7319-26.
15. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
16. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-65.
17. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014; 4: 650-61.
18. Sueoka-Aragane N, Sato A, Kobayashi N et al. Correlation between plasma DNA and tumor status in an animal model. PLoS ONE 2014; 9: e111881.
19. Uramoto H, Yamada T, Yano S et al. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Anticancer Res 2012; 32: 3785-90.
20. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17: 1169-80.
21. Hata A, Katakami N, Yoshioka H et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 2013; 119: 4325-32.
22. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
23. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
24. Suda K, Murakami I, Katayama T et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 5489-98.
25. Sundaresan TK, Sequist LV, Heymach JV et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 2015; Epub ahead of print.
26. Asada K, Oda K, Nishijima A et al. Cell free DNA and ascites might reflect tumor heterogeneity in ovarian carcinomas. P-2389, 74th Annual Meeting of the Japanese Cancer Association, Nagoya, October 8-10, 2015.